Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Trea... | NCT06048367

Description Module

Detailed Description

Indications: This study targets patients with advanced solid tumors who have either failed standard treatments (progression or intolerance) or lack available standard treatment options. Common tumor types include colorectal, pancreatic, breast, gastric, cervical, lung, head and neck, and prostate cancers.

Objectives: The primary goal is to assess the safety and tolerability of intratumoral injections of Carbon Nanoparticle Loaded Iron [CNSI-Fe(II)] in advanced solid tumor patients. This involves identifying dose-limiting toxicities (DLT) and determining the maximum tolerated dose (MTD) or highest injectable dose for subsequent clinical dosing decisions. Secondary objectives include evaluating the pharmacokinetics (PK) of CNSI-Fe(II) and its preliminary efficacy. Exploratory objectives is to understand the pharmacodynamics (PD) of CNSI-Fe(II), exploring the relationship between tumor size, injection dose, and drug concentration.

Participants: Up to 30 subjects will participate across 3 to 6 centers, with the final number dependent on dose group evaluations and tolerability.

Exit Criteria: Subjects may be withdrawn by researchers if they deviate from the protocol, impacting safety or efficacy assessment. Subjects can also voluntarily withdraw per guidelines, and their reasons will be documented. Efforts will be made to complete assessments for withdrawn cases.

Dose Selection: Based on animal toxicology and effective dose data, a starting dose of 0.5 mg/kg (escalating to 30 mg, 60 mg and 90 mg) is selected. Adjustments may occur if DLT is observed or MTD is not reached.

As of March 28, 2024, only one case of DLT occurred in the 90 mg dose group among the 30 mg, 60 mg, and 90 mg dose groups, demonstrating favorable safety and tolerability. The study has successfully passed the SRC meeting, allowing for further dose exploration at 120 mg, 150 mg, and potentially higher doses. Therefore, this protocol is hereby revised.

Study Design: This open-label Phase I trial assesses CNSI-Fe(II) intratumoral injections in advanced solid tumor patients. The study includes screening, treatment (with DLT evaluation), and follow-up phases.

Dose Escalation: The "3+3 method" guides dose escalation. Enrollment occurs in dose groups; dose escalation decisions are based on DLT occurrence.

DLT Evaluation: DLTs are defined using toxicity criteria, assessed during the first cycle (21 days). Escalation decisions depend on DLT occurrence.

DLT is defined as toxicities that are considered definitely or possibly related to the investigational drug CNSI-Fe(II) and occur within the first cycle (21 days) after the first dose. This includes Grade 4 hematological toxicity, Grade 3 hematological toxicity lasting >7 days after optimal treatment, Grade 3 thrombocytopenia with bleeding or requiring platelet transfusion, and Grade 3 neutropenia with fever.

Non-hematological toxicity:

Grade 3 cardiac toxicity lasting more than 3 days after optimal treatment or Grade 4 cardiac toxicity.
Grade 3 liver toxicity (for subjects with liver or bone metastasis and baseline liver enzyme ALT, AST, or ALP at Grade 2, ALT, AST, or ALP >10×ULN) lasting more than 3 days after optimal treatment or Grade 4 liver toxicity.
Any Grade 3 non-hematological toxicity (excluding laboratory abnormalities) lasting more than 7 days after optimal treatment, except for Grade 3 nausea, Grade 3 vomiting, or Grade 3 diarrhea.
Any Grade 4 non-hematological toxicity (excluding laboratory abnormalities).
Any Grade 3 or 4 non-hematological laboratory abnormality if it requires medical intervention, leads to hospitalization, or persists at Grade 3 or above for 7 days or more after discontinuation of the drug.

Other:

Any Grade 5 toxicity.
Other toxicities requiring early termination of CNSI-Fe(II) treatment as decided by the investigator and sponsor.

Besides evaluating the safety and tolerability of CNSI-Fe(II), this study will also preliminarily assess the efficacy of CNSI-Fe(II) in patients with advanced solid tumors. The investigator will evaluate CNSI-Fe(II)'s efficacy based on imaging examinations (computed tomography [CT], positron emission tomography [PET]/CT, or magnetic resonance imaging [MRI]), following the revised RECIST v1.1 criteria. Baseline imaging evaluations will be conducted within 28 days before the first treatment in the study. Subsequent tumor assessments will be performed for all subjects in the study at weeks 3-4 and, for those entering the maintenance phase, at weeks 7-8. Confirmation will be required for subjects achieving a complete response (CR) or partial response (PR) at least 4 weeks after the initial response. Baseline evaluations must include chest, abdomen, pelvis, skull (to exclude brain metastases), and other suspected tumor sites. Subsequent evaluations should reassess all measurable and evaluable lesions identified at baseline, including chest, abdomen, pelvis, and other suspected tumor sites. The imaging methods used for efficacy evaluation during the study must be consistent with the baseline imaging evaluation.

Medicinal Products: The study uses CNSI-Fe(II) consisting of a nanoparticle carbon dispersion injection and injectable ferrous sulfate.

Preparation of CNSI-Fe(II): Take one vial of injectable ferrous sulfate, keeping the aluminum cap and rubber stopper tightly closed and removing only the plastic outer cap of the aluminum-plastic combination cap. Slowly draw an appropriate amount of nanoparticle carbon dispersion injection using a suitable syringe and inject it into the vial containing ferrous sulfate, ensuring the solution is thoroughly mixed. The preparation of CNSI-Fe(II) should be done under aseptic conditions, avoiding exposure to air. It should be prepared and used at room temperature within 6 hours.

Dosing: Dosing varies per phase and dose group, ensuring administration within the target tumor.

PK and PD Analysis: Concentration-time curves, AUC, Cmax, Tmax, and PD marker levels are assessed using descriptive statistics.

Statistical Analysis: Descriptive statistics are employed for demographic, safety, efficacy, and PK/PD data. No formal hypothesis testing is planned.

Study Duration: The study will continue from the approval of the study by the Ethics Committee (EC) until the expected sample size is reached, subject to actual circumstances. The study is anticipated to end 28 days after the last subject has received a maximum of two doses of the study drug. After the study is completed, subjects who continue to achieve Complete Response (CR) or Partial Response (PR) and are determined by the investigator to still benefit from the treatment can continue to receive the study drug as a gift until disease progression, intolerable toxicity, or the investigator determines it is not appropriate to continue the study drug or the sponsor terminates the study.

Label	Type	Description	Intervention Names
CNSI-Fe(II) 30 mg	Experimental	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.	Drug: CNSI-Fe(II) 30 mg
CNSI-Fe(II) 60 mg	Experimental	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.	Drug: CNSI-Fe(II) 60 mg
CNSI-Fe(II) 90 mg	Experimental	90 mg CNSI-Fe(II) 90 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Name	Type	Description	Arm Group Labels	Other Names
CNSI-Fe(II) 30 mg	Drug	The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Measure	Description	Time Frame
Safety and Tolerability Assessment of CNSI-Fe(II)	This primary outcome measure is centered on the assessment of CNSI-Fe(II)'s safety and tolerability throughout the study. It encompasses the following assessments: Dose-Limiting Toxicity (DLT): This assessment involves the ongoing monitoring of adverse events, with a focus on determining their nature, severity, and frequency. Adverse events will be systematically categorized and reported according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Maximum Tolerated Dose (MTD): The MTD is a critical outcome measure representing the highest injectable dose in humans that can be safely administered without causing excessive adverse effects. The determination of MTD will be based on the careful observation and analysis of DLT data. The MTD was not determined in this Phase I study, and the MAD is 150mg. Units of Measure: DLT: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0. MTD: Milligrams (mg) of CNSI-Fe(II).	21 days

Measure	Description	Time Frame
PK Parameters Assessment: Cmax (ng/mL) Profile Assessment of CNSI-Fe(II) of First Dosage	This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors. Assessment Details: PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The first assessed parameter is maximum plasma concentration (Cmax). Cmax of first dosage Units of Measure: Cmax: Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible:
1. Understand and voluntarily sign the informed consent form (ICF), demonstrating willingness and ability to comply with all trial requirements.
2. Male or female aged 18-80 years (inclusive) at the time of signing the ICF.
3. Histologically or cytologically confirmed advanced solid tumors with ineffective current standard therapy (disease progression after treatment or intolerable treatment) or lack of effective standard treatment options. Eligible tumor types include colorectal cancer, pancreatic cancer, breast cancer, gastric cancer, cervical cancer, lung cancer, head and neck cancer, bile duct cancer, kidney cancer, prostate cancer, vulvar cancer, etc. Note: Patients with advanced solid tumors experiencing disease progression due to the inability to receive standard treatment for any reason or those with tumor types insensitive to existing standard treatments (e.g., pancreatic cancer, undifferentiated thyroid cancer, and sarcomas) after receiving first-line standard treatment are also eligible.
4. Presence of at least one measurable lesion according to RECIST v1.1, which has not received radiation (except for lesions showing clear progression after radiation) or tissue biopsy within 7 days before the first dose.
5. Lesions amenable to injection, either directly or with assistance from medical imaging.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 7 days before the first dose.
7. Expected survival of ≥12 weeks.
8. Adverse drug reactions (ADR) caused by previous treatments have recovered to Grade 1 or lower (except for alopecia) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 before screening.
9. Left ventricular ejection fraction (LVEF) ≥50%.
10. Within 7 days prior to the first dose, have adequate hematologic and end-organ function, with laboratory tests meeting the following criteria:
  1. Hematology No use of granulocyte colony-stimulating factor (G-CSF) within 14 days prior to hematology laboratory tests, and absolute neutrophil count (ANC) ≥1.5×109/L; No platelet transfusion within 14 days prior to hematology laboratory tests, and platelet count (PLT) ≥90×109/L; No blood transfusion or use of erythropoietin within 14 days prior to hematology laboratory tests, and hemoglobin (Hb) ≥90 g/L;
  2. Renal function Serum creatinine (Cr) ≤1.5×upper limit of normal (ULN) or calculated creatinine clearance (Ccr) ≥50 mL/min using the Cockcroft-Gault formula (only calculated if baseline Cr >1.5×ULN);
  3. Hepatic function Total bilirubin (TBIL) ≤1.5×ULN (≤3.0×ULN for patients with Gilbert's syndrome or liver metastases);
    
    Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤3×ULN, patients with confirmed liver or bone metastases must meet the following criteria:
    
    Patients with confirmed liver metastases: AST and ALT ≤5×ULN; Patients with confirmed bone metastases: ALP ≤5×ULN; Serum albumin ≥2.8 g/dL;
  4. Coagulation function International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5×ULN; Note: For patients with injectable lesions in the skin and/or subcutaneous tissue who are receiving anticoagulant therapy, prolonged INR, PT and aPTT are allowed, as bleeding can be controlled by direct pressure application, as determined by the investigator.
11. Women of childbearing potential (WOCBP) must have a negative pregnancy test result within 7 days before the first dose and agree to use effective contraception or practice abstinence during the study treatment period and for 6 months after the end of the study treatment. In addition, female patients must be non-lactating and agree not to donate eggs during this period. Note: WOCBP refers to non-sterilized women who have experienced menarche but have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not postmenopausal. Postmenopausal status is defined as continuous amenorrhea for ≥12 months in a woman over 45 years old without any other biological or physiological reasons. In addition, women under 55 years old must have serum follicle-stimulating hormone (FSH) levels >40 mIU/mL to be confirmed as postmenopausal. Hormone replacement therapy (HRT) can artificially suppress FSH levels in women and may require a washout period to return to physiological FSH levels. The recommended washout periods are as follows: vaginal hormone preparations (1 week), transdermal preparations (4 weeks), oral preparations (8 weeks), and other non-oral gastrointestinal preparations (up to 6 months). Postmenopausal status can be considered if the serum FSH level is >40 mIU/mL during the washout period.
12. Male patients must agree to use effective contraception or practice abstinence during the study treatment period and for 6 months after the end of the study treatment. In addition, male patients must agree not to donate sperm during this period.

Exclusion Criteria:

Patients meeting any of the following criteria cannot participate in this clinical study:
1. History of iron metabolism disorders (except for patients with iron-deficiency anemia), such as thalassemia or glucose-6-phosphate dehydrogenase deficiency.
2. History or current evidence of hollow organ perforation at the injection site.
3. History or current skin breakdown, redness, swelling, necrosis, or bleeding at the injection site that may affect the administration of the investigational drug.
4. Received radiotherapy or any antineoplastic therapy for the target lesion within 4 weeks before the first dose of the investigational drug or not reached 5 half-lives of the previous antineoplastic treatment [including but not limited to chemotherapy, targeted therapy, immunotherapy, National Medical Products Administration (NMPA) approved antineoplastic traditional Chinese medicine, and other traditional Chinese medicines with antitumor effects] before the first dose, whichever is shorter.
5. Undergone major surgical intervention, significant trauma, or have wounds or ulcers that have not healed within 4 weeks before the first dose.
6. Presence of life-threatening clinical manifestations of brain and central nervous system metastases at the time of enrollment.
7. Poorly controlled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg).
8. Uncontrolled tumor-related pain.
9. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once per month or more frequently).
10. History of other malignancies within 5 years before the start of study treatment, except for non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, stage I uterine cancer, cervical intraepithelial neoplasia, or stage 0 breast cancer after curative treatment.
11. Received live virus vaccines within 4 weeks before the start of study treatment. Note: Seasonal influenza vaccines administered by injection are usually inactivated, and their use is permitted. However, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
12. History of immunodeficiency diseases, including human immunodeficiency virus (HIV) positivity or acquired or congenital immunodeficiency diseases or organ transplantation.
13. Active hepatitis B virus (HBV) infection [positive for HBV surface antigen (HBsAg) or HBV core antibody (HBcAb) and HBV DNA quantification >500 IU/mL], hepatitis C virus (HCV) infection [positive for HCV antibody and HCV ribonucleic acid (RNA) measured by polymerase chain reaction (PCR) above the upper limit of normal (ULN)], or positive anti-human immunodeficiency virus antibody (Anti-HIV). Patients meeting any of these criteria are excluded.
14. Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment within 4 weeks before the start of study treatment, excluding diagnostic procedures.
15. Severe cardiovascular diseases, including but not limited to acute coronary syndrome or history of coronary artery revascularization/stent placement/bypass grafting within the past 6 months, or New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF), or history of NYHA Class III or IV CHF.
16. Active psychiatric disorders (e.g., schizophrenia, severe major depressive disorder, bipolar disorder, etc.).
17. Known allergies or intolerance to the active ingredient, excipients, or other iron supplements of the investigational drug.
18. Participated in other interventional clinical studies within 4 weeks before the start of the study treatment (from the first day after the last dose of the previous study, excluding interventions involving investigational drugs or medical devices).
19. Other conditions determined by the investigator that make the patient unsuitable for participation in this trial.

Name	Affiliation	Role
Yongsheng Wang, PhD & MD	West China Hospital	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
West China Hospital, Sichuan University		Chengdu	Sichuan	610041	China

PubMed Identifier	Type	Citation	Retractions
27668795	Background	Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, Pajarinen JS, Nejadnik H, Goodman S, Moseley M, Coussens LM, Daldrup-Link HE. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016 Nov;11(11):986-994. doi: 10.1038/nnano.2016.168. Epub 2016 Sep 26.
30911166

ID	Title	Description
FG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot_SAP	Yes	Yes	No	Study Protocol and Statistical Analysis Plan	Mar 28, 2024

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Safety and Tolerability Assessment of CNSI-Fe(II)

This primary outcome measure is centered on the assessment of CNSI-Fe(II)'s safety and tolerability throughout the study. It encompasses the following assessments:

Dose-Limiting Toxicity (DLT): This assessment involves the ongoing monitoring of adverse events, with a focus on determining their nature, severity, and frequency. Adverse events will be systematically categorized and reported according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Maximum Tolerated Dose (MTD): The MTD is a critical outcome measure representing the highest injectable dose in humans that can be safely administered without causing excessive adverse effects. The determination of MTD will be based on the careful observation and analysis of DLT data.

The MTD was not determined in this Phase I study, and the MAD is 150mg.

Units of Measure:

DLT: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0.

MTD: Milligrams (mg) of CNSI-Fe(II).

Posted

Count of Participants

Participants

21 days

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG002	CNSI-Fe(II) 90 mg	90 mg CNSI-Fe(II) 90 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG003	CNSI-Fe(II) 120 mg	120 mg CNSI-Fe(II) 120 mg: The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
OG004	CNSI-Fe(II) 150 mg	150 mg CNSI-Fe(II) 150 mg: The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.

Units	Counts
Participants	OG0003 OG0013 OG0026 OG003

Title

Denominators

Categories

Title	Measurements
Number of patients with DLT	OG0000 OG0010 OG0021 OG003

Secondary

PK Parameters Assessment: Cmax (ng/mL) Profile Assessment of CNSI-Fe(II) of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The first assessed parameter is maximum plasma concentration (Cmax).

Cmax of first dosage

Units of Measure:

Cmax: Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Tmax (h) Profile Assessment of CNSI-Fe(II) of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The second assessed parameter is time to maximum plasma concentration (Tmax).

Tmax of first dosage

Units of Measure:

Tmax: Hours (h)

Posted

Mean

Standard Deviation

time (h)

72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: AUC (ng•h/mL) Profile Assessment of CNSI-Fe(II) of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The third assessed parameter is area under the concentration-time curve (AUC).

AUC of first dosage

Units of Measure:

AUC: Nanograms per hour per milliliter (ng•h/mL)

Posted

Mean

Standard Deviation

h*ng/mL

72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: t1/2 (h) Profile Assessment of CNSI-Fe(II) of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fourth assessed parameter is elimination half-life (t1/2).

t1/2 of first dosage

Units of Measure:

t1/2: Hours (h)

Posted

Mean

Standard Deviation

time (h)

72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

Evaluated as CR (Complete Response) in the Preliminary Efficacy Assessment.

Complete Response (CR): According to the modified Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (lesions treated with local injection are defined as target lesions, and lesions not treated with local injection are defined as non-target lesions), target lesions are evaluated by contrast-enhanced CT/MRI. All target lesions must disappear, and the short diameter of all pathological lymph nodes must decrease to <10 mm.

Posted

Count of Participants

Participants

Observation period for a single dose is 21~28 days, the observation period for two doses is doubled.

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

Evaluated as PR (Partial Response) in the Preliminary Efficacy Assessment.

Partial Response (PR): According to the modified RECIST v1.1 (lesions treated with local injection are defined as target lesions, and lesions not treated with local injection are defined as non-target lesions), target lesions are evaluated by contrast-enhanced CT/MRI. The sum of the diameters of target lesions must decrease by at least 30% compared to baseline.

Posted

Count of Participants

Participants

Observation period for a single dose is 21~28 days, the observation period for two doses is doubled.

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

Evaluated as SD (Stable Disease) in the Preliminary Efficacy Assessment.

Stable Disease (SD): According to the modified RECIST v1.1 (lesions treated with local injection are defined as target lesions, and lesions not treated with local injection are defined as non-target lesions), target lesions are evaluated by contrast-enhanced CT/MRI. The reduction in target lesions does not meet the criteria for PR, and the increase does not meet the criteria for Progressive Disease (PD). The smallest sum of diameters observed during the study is used as a reference.

Posted

Count of Participants

Participants

Observation period for a single dose is 21~28 days, the observation period for two doses is doubled.

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

Evaluated as PD (Progressive Disease) in the Preliminary Efficacy Assessment.

Progressive Disease (PD): According to the modified RECIST v1.1 (lesions treated with local injection are defined as target lesions, and lesions not treated with local injection are defined as non-target lesions), target lesions are evaluated by contrast-enhanced CT/MRI. The sum of the diameters of target lesions increases by at least 20% compared to the smallest sum recorded during the study (or baseline if it is the smallest).

Posted

Count of Participants

Participants

Observation period for a single dose is 21~28 days, the observation period for two doses is doubled.

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Cmax (ng/mL) Profile Assessment of CNSI-Fe(II) of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

Cmax of second dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible. Therefore, only data from the 60 mg and 90 mg dose cohorts were included.

Units of Measure:

Cmax: Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

72 h post second dosage (The second dosing occurs 22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Tmax (h) Profile Assessment of CNSI-Fe(II) of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The second assessed parameter is time to maximum plasma concentration (Tmax).

Tmax of second dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Therefore, only data from the 60 mg and 90 mg dose cohorts were included.

Units of Measure:

Tmax: Hours (h)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

time (h)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: AUC (ng•h/mL) Profile Assessment of CNSI-Fe(II) of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The third assessed parameter is area under the concentration-time curve (AUC).

AUC of second dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

AUC: Nanograms per hour per milliliter (ng•h/mL)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

h*ng/mL

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: t1/2 (h) Profile Assessment of CNSI-Fe(II) of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fourth assessed parameter is elimination half-life (t1/2).

t1/2 of second dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

t1/2: Hours (h)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

time (h)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 1 h Before First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at -1 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at -1 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001

Secondary

PK Parameters Assessment: Serum Iron Concentration at 5 Min of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 5 min of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 5 min of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001

Secondary

PK Parameters Assessment: Serum Iron Concentration at 10 Min of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 10 min of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 10 min of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001

Secondary

PK Parameters Assessment: Serum Iron Concentration at 15 Min of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 15 min of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 15 min of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001

Secondary

PK Parameters Assessment: Serum Iron Concentration at 30 Min of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 30 min of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 30 min of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001

Secondary

PK Parameters Assessment: Serum Iron Concentration at 1 h of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 1 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 1 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Serum Iron Concentration at 2 h of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 2 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 2 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Serum Iron Concentration at 4 h of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 4 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 4 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Serum Iron Concentration at 8 h of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 8 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 8 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Serum Iron Concentration at 12 h of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 12 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 12 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Serum Iron Concentration at 24 h of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 24 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 24 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Serum Iron Concentration at 48 h of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 48 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 48 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Serum Iron Concentration at 72 h of First Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 72 h of first dosage

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 72 h of a time frame of 72 h

ID	Title	Description
OG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
OG001	CNSI-Fe(II) 60 mg

Secondary

PK Parameters Assessment: Serum Iron Concentration at 1 h Before Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at -1 h of second dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

1 h (of a time frame of 72 h) before second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 5 Min of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 5 min of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 5 min (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 10 Min of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 10 min of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 10 min (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 15 Min of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 15 min of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 15 min (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 30 Min of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 30 min of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 30 min (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 1 h of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 1 h of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 1 h (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 2 h of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 2 h of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 2 h (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 4 h of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 4 h of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 4 h (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 8 h of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 8 h of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 8 h (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 12 h of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 12 h of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 12 h (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 24 h of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 24 h of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 24 h (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 48 h of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 48 h of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 48 h (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Secondary

PK Parameters Assessment: Serum Iron Concentration at 72 h of Second Dosage

This secondary outcome measure focuses on assessing the pharmacokinetic (PK) profile of CNSI-Fe(II) in patients with advanced solid tumors.

Assessment Details:

PK Parameters Assessment: This assessment involves the analysis of the drug's absorption, distribution, metabolism, and excretion (ADME) in patients. It will provide insights into how CNSI-Fe(II) behaves in the human body. The fifth assessed parameter is serum iron concentration.

Serum iron concentration at 72 h of first dosage: The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively. Due to the requirement for mean ± SD data presentation, the number of evaluable subjects in 30 mg, 120 mg, 150 mg groups was fewer than two, making SD calculation impossible.

Units of Measure:

Nanograms per milliliter (ng/mL) (serum iron ion concentrations changes from baseline)

The number of patients receiving the second dose in the 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg dose groups was: 1, 2, 3, 1, and 0, respectively.

Posted

Mean

Standard Deviation

concentration (ng/mL)

at 72 h (of a time frame of 72 h) of second dosage (22~35 days after first dosing. For patient in 30 mg group, 23 days; for patients in 60 mg group, 26 and 22 days; for patients in 90 mg group, 23, 35 and 28 days; for patient in 120 mg group, 28 days.)

ID	Title	Description
OG000	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Five dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.	0	3	1	3	3	3
EG001	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Five dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.	0	4	1	4	4	4
EG002	CNSI-Fe(II) 90 mg	90 mg CNSI-Fe(II) 90 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Five dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.	2	6	5	6	6	6
EG003	CNSI-Fe(II) 120 mg	120 mg CNSI-Fe(II) 120 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Five dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.	0	3	0	3	3	3
EG004	CNSI-Fe(II) 150 mg	150 mg CNSI-Fe(II) 150 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Five dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.	0	3	1	3	3	3

Other Adverse Events

Term	Organ System	Assessment Type	Statistical Information
injection site pain	Surgical and medical procedures	Systematic Assessment	EG0003 events3 affected3 at risk EG0015 events4 affected4 at risk EG0026 events5 affected6 at risk EG0033 events3 affected3 at risk EG0042 events2 affected3 at risk
weak	General disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0014 events2 affected4 at risk EG0024 events3 affected6 at risk EG003
fever	General disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0024 events3 affected6 at risk EG003
pain	General disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
injection site swelling	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected3 at risk EG0012 events2 affected4 at risk EG0020 events0 affected6 at risk EG003
injection site reaction	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0022 events2 affected6 at risk EG003
Facial edema	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0022 events2 affected6 at risk EG003
Peripheral edema	General disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
stethalgia	General disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
foreign body sensation	General disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Injection site warmth	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
elevation of blood pressure	Vascular disorders	Systematic Assessment	EG0003 events1 affected3 at risk EG0013 events2 affected4 at risk EG0023 events2 affected6 at risk EG003
Elevated serum iron	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0012 events2 affected4 at risk EG0025 events4 affected6 at risk EG003
Lymphocyte count decreased	Investigations	Systematic Assessment	EG0003 events1 affected3 at risk EG0012 events2 affected4 at risk EG0023 events3 affected6 at risk EG003
decreased white blood cell count	Investigations	Systematic Assessment	EG0002 events2 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Alanine aminotransferase elevation	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0013 events2 affected4 at risk EG0022 events2 affected6 at risk EG003
Elevated platelet count	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0023 events3 affected6 at risk EG003
neutrophil count decrease	Investigations	Systematic Assessment	EG0003 events2 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Elevated white blood cell count	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0021 events1 affected6 at risk EG003
Urine leukocyte positive	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Abnormal T wave of ECG	Investigations	Systematic Assessment	EG0001 events1 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Elevated heart rate	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0022 events2 affected6 at risk EG003
hypoalbuminia	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Elevated neutrophil count	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0021 events1 affected6 at risk EG003
elevated C-reactive protein	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Alpha-Hydroxybutyrate Dehydrogenase (α-HBDH) Elevation	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
decrease of binding capacity of unsaturated iron	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Elevated Amylase	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Increased Respiratory Rate	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Elevated Procalcitonin	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Decreased Lymphocyte Percentage	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Positive Urine Occult Blood	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Presence of Urine Ketones	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Decreased Eosinophil Percentage	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Weight Loss	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Elevated Aspartate Aminotransferase	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Abnormal ST ESG	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Increased Cardiac Necrosis Markers	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Elevated Blood Bilirubin	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Elevated Blood Creatinine	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Elevated Alkaline Phosphatase	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Elevated Blood Glucose	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Elevated serum ferritin	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Elevated blood lactate	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Elevated lactate dehydrogenase	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Platelet count decreased	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Blood pressure decreased	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Lipase elevated	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0022 events1 affected6 at risk EG003
Neutrophil percentage increased	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Transferrin saturation abnormal	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Total protein decreased	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Total iron-binding capacity increased	Investigations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Hyponatremia	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0023 events2 affected6 at risk EG003
Hypoalbuminemia	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0023 events3 affected6 at risk EG003
Reduced food intake	Metabolism and nutrition disorders	Systematic Assessment	EG0002 events2 affected3 at risk EG0011 events1 affected4 at risk EG0022 events2 affected6 at risk EG003
Hypertriglyceridemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0012 events2 affected4 at risk EG0023 events2 affected6 at risk EG003
Decreased appetite	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Hypokalemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0012 events1 affected4 at risk EG0021 events1 affected6 at risk EG003
Hypocalcemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0022 events1 affected6 at risk EG003
Hypomagnesemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Hyperglycemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Iron overload	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Difficulty breathing	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0022 events2 affected6 at risk EG003
Hemoptysis	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Pneumothorax	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Paranasal sinus inflammation	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Dysphonia	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Productive cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
anemia	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0012 events2 affected4 at risk EG0025 events3 affected6 at risk EG003
COVID-19	Infections and infestations	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Abdominal wall abscess	Infections and infestations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
pneumonia	Infections and infestations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Focal peritonitis	Infections and infestations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Oral infection	Infections and infestations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Urinary tract infection	Infections and infestations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Upper respiratory tract infection	Infections and infestations	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Infectious exacerbation of bronchiectasis	Infections and infestations	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Dizziness	Nervous system disorders	Systematic Assessment	EG0003 events1 affected3 at risk EG0012 events1 affected4 at risk EG0022 events2 affected6 at risk EG003
Headache	Nervous system disorders	Systematic Assessment	EG0002 events1 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Hypoesthesia	Nervous system disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Parageusia	Nervous system disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Limb pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Muscle twitching	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Disc disease	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Cancer pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0023 events2 affected6 at risk EG003
Malignant tumor progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0023 events3 affected6 at risk EG003
Hyperhidrosis	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Rash	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0003 events1 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Hypotension	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Pallor	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Superficial vein thrombosis	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Abnormal liver function	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Chronic cholecystitis	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Dysuria	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0022 events2 affected6 at risk EG003
palpitation	Cardiac disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Blurred vision	Eye disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Eye congestion	Eye disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Periorbital edema	Eye disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Prescription drug overdose	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Hypersensitivity reaction	Immune system disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Nausea	Gastrointestinal disorders	Systematic Assessment	EG0004 events2 affected3 at risk EG0010 events0 affected4 at risk EG0022 events1 affected6 at risk EG003
Vomiting	Gastrointestinal disorders	Systematic Assessment	EG0002 events1 affected3 at risk EG0011 events1 affected4 at risk EG0024 events3 affected6 at risk EG003
Constipation	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003
Abdominal discomfort	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Abdominal distension	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0023 events1 affected6 at risk EG003
Reduced oral sensation	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0022 events1 affected6 at risk EG003
Abdominal tenderness	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Abdominal pain	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Diarrhea	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Retching	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0020 events0 affected6 at risk EG003
Colonic fistula	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Oral bleeding	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0023 events1 affected6 at risk EG003
Upper gastrointestinal bleeding	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Toothache	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0010 events0 affected4 at risk EG0021 events1 affected6 at risk EG003
Hemorrhoidal bleeding	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected3 at risk EG0011 events1 affected4 at risk EG0020 events0 affected6 at risk EG003

ID	Term
D008175	Lung Neoplasms
D010190	Pancreatic Neoplasms
D001943	Breast Neoplasms
D013964	Thyroid Neoplasms
D015179	Colorectal Neoplasms
D002583	Uterine Cervical Neoplasms
D010051	Ovarian Neoplasms
D014846	Vulvar Neoplasms

ID	Term
D012142	Respiratory Tract Neoplasms
D013899	Thoracic Neoplasms
D009371	Neoplasms by Site
D009369	Neoplasms
D008171	Lung Diseases
D012140	Respiratory Tract Diseases
D004067	Digestive System Neoplasms
D004701	Endocrine Gland Neoplasms
D004066	Digestive System Diseases
D010182	Pancreatic Diseases
D004700	Endocrine System Diseases
D001941	Breast Diseases
D012871	Skin Diseases
D017437	Skin and Connective Tissue Diseases
D006258	Head and Neck Neoplasms
D013959	Thyroid Diseases
D007414	Intestinal Neoplasms
D005770	Gastrointestinal Neoplasms
D005767	Gastrointestinal Diseases
D003108	Colonic Diseases
D007410	Intestinal Diseases
D012002	Rectal Diseases
D014594	Uterine Neoplasms
D005833	Genital Neoplasms, Female
D014565	Urogenital Neoplasms
D002577	Uterine Cervical Diseases
D014591	Uterine Diseases
D005831	Genital Diseases, Female
D052776	Female Urogenital Diseases
D005261	Female Urogenital Diseases and Pregnancy Complications
D000091642	Urogenital Diseases
D000091662	Genital Diseases
D010049	Ovarian Diseases
D000291	Adnexal Diseases
D006058	Gonadal Disorders
D014845	Vulvar Diseases

ID	Title	Description
BG000	CNSI-Fe(II) 30 mg	30 mg CNSI-Fe(II) 30 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
BG001	CNSI-Fe(II) 60 mg	60 mg CNSI-Fe(II) 60 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an dditional dose may be administered based aon the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
BG002	CNSI-Fe(II) 90 mg	90 mg CNSI-Fe(II) 90 mg: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
BG003	CNSI-Fe(II) 120 mg	120 mg CNSI-Fe(II) 120 mg: The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
BG004	CNSI-Fe(II) 150 mg	150 mg CNSI-Fe(II) 150 mg: The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
BG005	Total	Total of all reporting groups